The CEO of NeuroDerm Ltd. has been invited to discuss the company’s achievements at the Jefferies 2015 Healthcare Conference, taking place next month in New York. Oded S. Lieberman, PhD, will present a corporate overview of the company, as well as novel treatments being developed by NeuroDerm for the treatment of moderate to severe Parkinson’s disease.
The Israeli clinical stage pharmaceutical company is going to discuss on a panel presentation to be held on June 1, 3:30 pm ET, its next-generation therapies for diseases of the central nervous system, created to surpass the great unmet need for treatments and provide clinical efficacy with efficacy, with continuous and controlled drug delivery.
Lieberman will focus on NeuroDerm’s leading product candidates for Parkinson’s, including ND0612L for patients with moderate disease, and ND0612H, ND0680 and ND0701 for patients with severe disease. The company announced the presentation, as well as its live webcast on their website, which will remain available for a month after the conference.
ND0612L was developed by the company for patients who suffer from moderate Parkinson’s and cannot effectively manage the motor complications of the disease by taking the oral medical levodopa. It is prescribed as subcutaneous, continuous fixed-dose, 24-hour therapy and is expected to increase motor and non-motor abilities by maintaining steady plasma levodopa concentrations.
From the treatments for severe stages of the diseases, ND0612H is being studied for patients who no longer see effective results from oral drugs, and it is expected to become a more safe, effective and convenient therapy option, inclusive to surgery. ND0680 is meant for patients needing particularly high doses of LD/CD that cannot be delivered orally or through ND0612L and ND0612H.
ND0701 is an apomorphine-based investigational therapy expected to provide a next-generation therapeutic choice in comparison to the continuously administered apomorphine product currently used in other countries. NeuroDerm is committed to improving local tolerability and safety, which are challenges faced by apomorphine products, as well as to enable an easier and lower daily administration volume.
In addition to the treatments for Parkinson’s disease, NeuroDerm is also developing ND0801 for the treatment of cognition disorders related to the central nervous system diseases, including Attention Deficit Disorder/Attention Deficit Hyperactivity Disorder (ADD/ADHD), Alzheimer’s disease and schizophrenia, as well as Parkinson’s disease.